1st treatment for EGFR+* NSCLC
RYBREVANT® and LAZCLUZE™ are targeted treatments that work together to fight cancer without needing chemotherapy
RYBREVANT® is a targeted antibody† that works against by:
Helping stop the activity cancer cells use to grow and spread
Working with your body's immune system to help destroy the cancer
LAZCLUZE™ is an EGFR-targeted TKI (tyrosine kinase inhibitor) that:
Helps stop the activity cancer cells use to grow and spread from inside the cancer cell
*Mutations include exon 19 deletion or exon 21 L858R substitution mutations.
†Antibodies are protective proteins that help detect harmful substances and diseases such as cancers. They are made naturally by your immune system and can also be man-made. Man-made antibodies used to treat cancer have a specific target on a cancer cell that they aim to find, attach to, and attack. RYBREVANT® is a man-made antibody.
EGFR+ = mutated epidermal growth factor receptor; NSCLC = non–small cell lung cancer
Side effects
There are side effects that you may experience during treatment with RYBREVANT® + LAZCLUZE™.
Savings & support
Once prescribed a RYBREVANT®-based treatment, connect with a Care Navigator for your support needs.
